For pulmonary arterial hypertension, currently marketed methods of treprostinil administration include intravenous, subcutaneous and inhalation. Oral treprostinil is actively being investigated.

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

Suggested remit: To appraise the clinical and cost effectiveness of Inhaled Treprostinil within its marketing authorisation for treating lung disease.

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

In a report released on January 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Insmed (INSM – Research Report), with a ...